Lexeo Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Lexeo Therapeutics, Inc. (LXEO) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -3.73% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2025-03-24
- Lexeo Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -3.73%.
- Lexeo Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was -4.80%, a 231.15% decline from fiscal 2022.
- Lexeo Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 3.66%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -3.73% 10-K · filed 2025-03-24 | |
| 2023-12-31 | -4.80% 10-K · filed 2025-03-24 | 4.80% 10-K · filed 2024-03-11 |
| 2022-12-31 | 3.66% 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |